Table 2.
Median levels of promising analytes as measured with the 29-plex assay
| Analyte | All subjects (n = 19) |
Active TB cases (n = 10) |
LTBI (n = 9) |
p-value (Active TB vs LTBI) |
| EGFNil | 73.0 (23.4–148.9) |
106.2 (40.8–148.9 |
51.4 (23.4–141.3 |
0.02 |
| IFN-γAg-Nil | 99.1 (0.0–1265.0) |
57.0 (0.0–646.3) |
127.6 (38.6–1265.5) |
0.08 |
| IP-10* Ag-Nil | 18139.0 (5313.0–>20000.0) |
14446.0 (5313.0–>20000.0) |
18224.0 (12470.0–>20000.0) |
0.27 |
| IL-2*Ag-Nil | 160.0 (10.2–1778.0) |
106.6 (10.2–640.9) |
164.0 (57.8–1778.0) |
0.19 |
| IL-1αAg-Nil | 76.6 (0.0–235.4) |
118.0 (0.0–235.4) |
23.3 (0.0–158.5) |
0.04 |
| MIP-1βAg-Nil | 1770 (0.0–7847.0) |
1210.0 (0.0–4098.0) |
3220 (960.8–7847.0) |
0.06 |
| TNF-αNil | 50.8 (7.3–633.7) |
94.9 (19.8–633.7) |
15.9 (7.3–293.6) |
0.01 |
| TGF-αNil | 13.3 (0.0–230.1) |
28.5 (0.0–230.1) |
6.2 (0.0–13.3) |
<0.01 |
|
VEGFAg-Nil |
0.0 (0.0–77.3) |
0.0 (0.0–31.8) |
36.3 (0.0–77.3) |
<0.01 |
|
sCD40LNil |
869.0 (245.2–9852.0) |
1388.0 (455.4–4038.0) |
599.4 (245.2–9852.0) |
0.03 |
| sCD40LAg-Nil | 0.0 (0.0–9944.0) |
0.0 (0.0–4.6) |
309.4 (12.2–9944.0) |
<0.01 |
Median levels (pg/ml) and ranges (in parenthesis) of analytes with significant or near significant differences between TB cases and the latently infected individuals obtained with the 29-plex assay. * Marker was not included in the customized 8-plex kit. Levels shown as >20000 pg/ml were above the highest point on the standard curve.